Treatment outcomes of pediatric patients on high dose pure fish oil‐based fat emulsion: A retrospective study
Nutrition in Clinical Practice · 2025
DOI: 10.1002/ncp.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrition in Clinical Practice, 2025. Verfasst von Anam Bashir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania,…. Hauptthemen laut MEDLINE: Fish Oils, Fat Emulsions, Intravenous, Parenteral Nutrition, Intestinal Failure. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
Pure fish oil‐based fat emulsion (FO‐ILE) dosed at 1 g/kg/day is FDA approved for the treatment of intestinal failure associated liver disease. However, this limited fat provision can lead to suboptimal weight gain and excessive caloric intake from dextrose, particularly in neonates. There is limited data on the use of FO‐ILE at doses higher than 1 g/kg/day. This study describes our experience with pediatric patients receiving 1.5 g/kg/day of FO‐ILE.
Methods
A retrospective chart review was performed on patients receiving parenteral nutrition aged 0–18 years and receiving FO‐ILE at a dose of 1.5 g/kg/day for at least 14 days. Clinical outcomes of interest included weight gain, glucose infusion rates (GIRs) and adverse effects including cholestasis, postprocedure hemorrhage, hypertriglyceridemia and essential fatty acid (EFA) deficiency.
Results
Nine patients (range 2 months–12.9 years) receiving 1.5 g/kg/day of FO‐ILE were included. Seven patients showed improved weight gain. Decrease of GIR was noted in four patients. One patient experienced worsening cholestasis with no clear etiology which prompted the decrease of FO‐ILE to 1 g/kg/day with later resolution of cholestasis. Seven patients underwent invasive procedures, with one patient experiencing more than expected bleeding after circumcision not necessitating a decrease in dose. None of the patients developed hypertriglyceridemia. Eight patients had an EFA panel collected, all within normal limits.
Conclusion
Our findings suggest that higher doses of FO‐ILE may be safe and beneficial in patients with suboptimal weight gain, and elevated GIR. Larger and long‐term studies are required to validate these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pharmacy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Clinical Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Anam Bashir
Zitieren
APA
Bashir, A., Karel, L., Begany, M., Blandine, A., Palpant, C., Paul, E., McCoy, T., Maqbool, A., & Panganiban, J. (2025). Treatment outcomes of pediatric patients on high dose pure fish oil‐based fat emulsion: A retrospective study. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.70014
Vancouver
Bashir A, Karel L, Begany M, Blandine A, Palpant C, Paul E, et al. Treatment outcomes of pediatric patients on high dose pure fish oil‐based fat emulsion: A retrospective study. Nutrition in Clinical Practice. 2025. doi:10.1002/ncp.70014
BibTeX
@article{Bashir2025,
author = {Bashir, Anam and Karel, Lauren and Begany, Meg and Blandine, Alexis and Palpant, Christine and Paul, Elizabeth and McCoy, Tana and Maqbool, Asim and Panganiban, Jennifer},
title = {Treatment outcomes of pediatric patients on high dose pure fish oil‐based fat emulsion: A retrospective study},
journal = {Nutrition in Clinical Practice},
year = {2025},
doi = {10.1002/ncp.70014}
}
EUVIMED